Claims

1.Use of an antagonist of a Programmed Death Ligand 1 protein (PD-L1) in the manufacture of a medicament for treating a cancer in a subject, wherein the PD-L1 antagonist is to be administered in combination with a VEGFR inhibitor, and wherein the PD-L1 antagonist is an anti-PD-L1 monoclonal antibody comprising three CDRs in the heavy chain variable region comprising amino acid sequences SEQ ID NO: 2, 3, and 4, and three CDRs in the light chain variable region comprising amino acid sequences SEQ ID NO: 5, 6, and 7, and wherein the VEGFR inhibitor is axitinib or a pharmaceutically acceptable salt thereof.

2.The use of claim 1, wherein the PD-L1 antagonist is to be administered as an initial dose of at least about 5 mg/kg, or about 10 mg/kg; and the VEGFR inhibitor is to be administered as an initial dose of at least 3 mg/kg or 5 mg/kg.

3.The use of claims 1 or 2, wherein the PD-L1 antagonist is to be administered about once every two weeks; and the VEGFR inhibitor is to be administered twice daily.

4.Use of a VEGFR inhibitor in the manufacture of a medicament for treating a cancer in a subject, wherein the VEGFR inhibitor is to be administered in combination with an antagonist of a Programmed Death Ligand 1 protein (PD-L1), and wherein the VEGFR inhibitor is axitinib or a pharmaceutically acceptable salt thereof, and wherein the PD-L1 antagonist is an anti-PD-L1 monoclonal antibody comprising three CDRs in the heavy chain variable region comprising amino acid sequences SEQ ID NO: 2, 3, and4, and three CDRs in the light chain variable region comprising amino acid sequences SEQ ID NO: 5, 6, and 7.

5.The use of any one of claims 1 to 4, wherein the cancer is renal cell carcinoma.

6.The use of any one of claims 1 to 5, wherein the PD-L1 antagonist is avelumab.

7.The use of claim 6, wherein the avelumab is formulated as a liquid medicament and axitinib is formulated as a 1 mg tablet, a 3 mg tablet, or a 5 mg tablet.

8.A kit when used according to the use of claim 1, comprising a first container, a second container and a package insert, wherein the first container comprises at least one dose of a medicament comprising an antagonist of a Programmed Death Ligand 1

protein (PD-L1), the second container comprises at least one dose of a medicament comprising a VEGFR inhibitor, and the package insert comprises instructions for treating a subject for cancer using the medicaments, wherein the PD-L1 antagonist is an anti-PD-L1 monoclonal antibody comprising three CDRs in the heavy chain variable region comprising amino acid sequences SEQ ID NO: 2, 3, and 4, and three CDRs in the light chain variable region comprising amino acid sequences SEQ ID NO: 5, 6, and 7, and wherein the VEGFR inhibitor is axitinib or a pharmaceutically acceptable salt thereof.

9.The kit of claim 8, wherein the instructions state that the medicaments are intended for use in treating a cancer in a subject that tests positive for PD-L1 expression by an immunohistochemical (IHC) assay.

10. The kit of claims 8 or 9, wherein the PD-L1 antagonist is avelumab formulated as a liquid medicament and the VEGFR inhibitor is axitinib formulated as a 1 mg tablet, a 3 mg tablet, or a 5 mg tablet.

11.The use, or kit of any one of claims 1 to 4, and 6 to 10, wherein the cancer is bladder cancer, breast cancer, clear cell kidney cancer, head/neck squamous cell carcinoma, lung squamous cell carcinoma, malignant melanoma, non-small-cell lung cancer (NSCLC), ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, small-cell lung cancer (SCLC), triple negative breast cancer, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin's lymphoma (HL), mantle cell lymphoma (MCL), multiple myeloma (MM), myeloid cell leukemia-1 protein (Mcl-1), myelodysplastic syndrome (MDS), non-Hodgkin's lymphoma (NHL), Squamous Cell Carcinoma of the Head and Neck (SCCHN), or small lymphocytic lymphoma (SLL).

12.The use, or kit of any of claims 1 to 4, and 6 to 10, wherein the cancer is advanced renal cell carcinoma, optionally previously untreated advanced renal cell carcinoma.